Enteris BioPharma offers innovative formulation solutions built around its proprietary oral delivery technology platform – Peptelligence™. Since its founding in 2013, Enteris BioPharma has advanced multiple internal and external programs leveraging its Peptelligence™ platform. The technology has been developed and proven effective to enable the safe delivery of peptide-based therapeutics and other molecules with low oral bioavailability.
“We are committed to delivering innovative medicines to meet unmet medical needs. Using our patented delivery technology, we are reformulating injectable molecules into novel oral products that will have significant medical and commercial impact.”
Joel Tune Chief Executive Officer
“We are focused on solving challenging formulation issues for our partners using our proprietary, cutting edge, delivery technology. Our combined strengths in formulation development and manufacturing uniquely position us to be an industry leader in overcoming the formulation challenges to deliver peptides and small molecules orally.”
Brian Zietsman President and Chief Financial Officer
“We are dedicated to providing our partners a turnkey solution that enables them to rapidly evaluate and implement our delivery technology in a robust pharmaceutical development strategy. With our proven capabilities, we are able to deliver a full 3.2.P filing package and Clinical Trial Material to allow partners quick entry into clinical evaluation.”